Literature DB >> 11734949

Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinoma.

V D Raptopoulos1, S P Blake, K Weisinger, M B Atkins, M T Keogan, J B Kruskal.   

Abstract

The aim of this study was to evaluate whether in patients with metastatic renal cell carcinoma (RCC) multiphase liver studies would improve detection of metastatic liver disease. Forty-six consecutive patients with known metastatic RCC underwent standardized non-contrast and triphasic contrast enhanced hepatic CT examinations as part of their routine imaging studies. Once a liver abnormality was detected, it was characterized as metastatic by a panel of three radiologists who followed pre-set criteria. These criteria included change in size, biopsy results and lack of benign features. Presence and conspicuity of liver metastases were graded using a five-point scale by consensus of a panel of three radiologists. The highest number of lesions evaluated per patient was limited to ten. Seventy-two liver metastases were detected in 16 patients. Of these, 54 were seen on unenhanced scans; 47 in the hepatic arterial (HA) phase, at 25 s; 65 in the portal-venous (PV) phase, at 60 s; and 49 in delayed images, at 90 s. Scanning only during the PV phase would have missed seven lesions (10%), six of which were seen on unenhanced images and six were seen in HA phase. All patients with metastatic liver disease would have been identified by combination of unenhanced and PV phase or by HA and PV phase scanning. Forty-two lesions were graded more conspicuous on the PV phase, whereas 18 (25%) were more conspicuous on the HA phase. The combination of unenhanced, HA and PV scanning should be considered in the initial evaluation of patients with metastatic RCC for improved lesion detection and characterization. Subsequently, the combination of unenhanced and PV phase imaging is preferred.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734949     DOI: 10.1007/s003300100853

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  7 in total

1.  Comparison of two contrast materials with different iodine concentrations in enhancing the density of the the aorta, portal vein and liver at multi-detector row CT: a randomized study.

Authors:  Hiromasa Suzuki; Hidekazu Oshima; Norio Shiraki; Chisa Ikeya; Yuta Shibamoto
Journal:  Eur Radiol       Date:  2004-08-12       Impact factor: 5.315

2.  Standardisation of liver MDCT by tracking liver parenchyma enhancement to trigger imaging.

Authors:  H Brodoefel; A Tognolini; G A Zamboni; S Gourtsoyianni; C D Claussen; V Raptopoulos
Journal:  Eur Radiol       Date:  2011-11-05       Impact factor: 5.315

3.  Re-evaluation of detectability of liver metastases by contrast-enhanced CT: added value of hepatic arterial phase imaging.

Authors:  Yukiko Honda; Toru Higaki; Haruka Higashihori; Yoshio Monzen; Fuminari Tatsugami; Shuji Date; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2014-05-23       Impact factor: 2.374

4.  Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.

Authors:  Paul Nathan; Anup Vinayan
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

Review 5.  Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

Authors:  Luís León; Roberto García-Figueiras; Roberto García-Figueras; Cristina Suárez; Antonia Arjonilla; Javier Puente; Blanca Vargas; Maria José Méndez Vidal; Carmen Sebastiá
Journal:  Target Oncol       Date:  2013-12-12       Impact factor: 4.493

6.  Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? - a single-center retrospective study.

Authors:  Florian Hagen; Felix Peisen; Jakob Spogis; Antonia Mair; Konstantin Nikolaou; Arnulf Stenzl; Stephan Kruck; Jens Bedke; Sascha Kaufmann; Wolfgang M Thaiss
Journal:  Cancer Imaging       Date:  2022-01-21       Impact factor: 3.909

Review 7.  Imaging Advances in the Management of Kidney Cancer.

Authors:  Katherine M Krajewski; Ivan Pedrosa
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.